Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04370041
Other study ID # DKPLUS2020
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date September 2, 2020
Est. completion date November 4, 2022

Study information

Verified date December 2022
Source Swan Medical S. L.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study intends to reinforce the current clinical information regarding safety and efficacy of the Dokimos Plus aortic valve prosthesis in patients in whom an aortic valve replacement with a bioprosthesis has been indicated.


Description:

Multicenter, non-randomized, longitudinal case series clinical trial designed to reinforce the current safety and efficacy clinical data of the Dokimos Plus aortic valve and renew the CE mark. The study foresees the inclusion of 80 patients recruited prospectively. Patients over 65 who have been diagnosed with a heart valve disease and who require surgical aortic valve replacement, or younger patients who are unsuitable for long-term anticoagulation due to medical contraindications or lifestyle considerations. The study will collect information on the Dokimos Plus aortic valve transvalvular gradient at 6 months and 12 months after the implantation. In addition, patients will be annually followed-up, up to 10 years after implantation. The objective of the study valve is to improve life expectancy and quality of life of patients with a diseased aortic valve, replacing it with a bioprosthesis that can be safely implanted, with good hemodynamics and long durability. Clinical studies carried out up to date have shown that the Dokimos Plus aortic valve presents satisfactory clinical and hemodynamic results, similar to those of other bioprothesis available on the market. In addition, the post-marketing surveillance carried out by the manufacturer has not revealed any relevant events regarding the Dokimos Plus aortic valve safety profile.


Recruitment information / eligibility

Status Terminated
Enrollment 80
Est. completion date November 4, 2022
Est. primary completion date November 4, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients over 18 2. Patients with the ability to understand the study requirements, be able to given written informed consent, and be willing and able to comply with the study requirements (including follow-up visits). 3. Patient candidates to an aortic bioprosthesis implantation according to the standard clinical practice guidelines. 4. Patients requiring isolated aortic valve replacement, or in combination with coronary artery bypass surgery and / or in combination with ascending aorta replacement surgery. 5. Women are eligible for the study if: a) are not pregnant or breastfeeding, b) are not of childbearing potential, c) if women of childbearing potential, a negative urine pregnancy test should be done within 48 hours before the intervention and must use an effective contraceptive method. Exclusion Criteria: 1. Cardiac surgery contraindications. 2. Patients who require other interventions than the isolated aortic valve replacement or with coronary artery bypass surgery and / or in combination with ascending aorta replacement surgery as concomitant procedure. 3. Patients with LVEF < 30%. 4. Cardiac surgery reintervention. 5. Cardiogenic shock or hemodynamic instability within 24 hours prior to surgery. 6. Patient who are not willing to attend to the required follow-up visit. 7. Patients with active endocarditis (in the case of cured endocarditis, the presence of at least two negative blood cultures must be confirmed before their inclusion in the study). 8. Patient undergoing hemodialysis or with severe renal impairment (eGFR<30ml/min/1,7m2). 9. Pregnant women. 10. Patients with hyperparathyroidism. 11. Life expectancy less than 2 years. 12. Patients with a history or diagnosis of a medical problem or psychiatric illness or disorder that, according to the investigator evaluation, would make the patient not eligible to participate in the study.

Study Design


Intervention

Device:
Dokimos Plus aortic valve
Dokimos Plus aortic valve

Locations

Country Name City State
Spain Hospital Germans Trias i Pujol Badalona Barcelona
Spain Hospital Clínic Barcelona Barcelona
Spain Hospital Universitario Bellvitge Hospitalet de Llobregat Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Swan Medical S. L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transvalvular gradient Dokimos Plus aortic valve transvalvular gradient at 6 months and at 12 months after the implantation. Up to 12 months
Secondary Number of participants with abasence of valve deterioration Assess the absence of structural valve deterioration (morphological and hemodynamic) after 12 months follow-up. 12 months
Secondary Number of participants with absence of non-structural valve deterioration Assess the absence of non-structural valve deterioration after 12 months follow-up. 12 months
Secondary Number of participants with absence of endocarditis or thrombosis Asses the absence of endocarditis or thrombosis. 10 years
Secondary Number of participants with need for prosthetic replacement Assess the need for prosthetic replacement. 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Completed NCT02834806 - BIONICS Israel Trial N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Withdrawn NCT00543348 - RCT of the Cutting Balloon Versus a High Pressure Balloon for the Treatment of Arteriovenous Fistula Stenoses N/A
Completed NCT00555659 - Prospective Clinical Evaluation of the New Aegis Plate for Anterior Interbody Fusions N/A
Completed NCT00205101 - Clinical Outcome Study of the Triad Allograft for Posterior Lumbar Fusion
Recruiting NCT05053932 - Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia
Completed NCT02373852 - PMS Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention
Completed NCT01970579 - Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter Phase 3
Completed NCT01873586 - OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion N/A
Completed NCT00540813 - Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions N/A
Recruiting NCT00496639 - Stent vs. Angioplasty for Treatment of Thrombosed AV Grafts: Long-Term Outcomes N/A
Terminated NCT00254852 - Evaluation of Radiographic and Patient Outcomes Following Lumbar Spine Fusion Using Demineralized Bone Matrix (DBM) Mixed With Autograft N/A
Enrolling by invitation NCT05583305 - Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
Completed NCT02018445 - Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion N/A
Withdrawn NCT03327272 - Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion Phase 3
Completed NCT04698512 - MAgicTouch™ Intervention Leap for Dialysis Access (MATILDA) Trial
Active, not recruiting NCT02428582 - Covered Stents Versus Bare-Metal Stents N/A
Completed NCT01742117 - Tailored Antiplatelet Therapy Following PCI Phase 4